RoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq - direct healthcare professional communication (DHPC)

tocilizumab / emicizumab / trastuzumab / trastuzumab emtansine / rituximab / pertuzumab / trastuzumab / atezolizumab

About

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Documents

Potential missing package leaflet in folding boxes of RoActemra (tocilizumab), Hemlibra (emicizumab), Herceptin (trastuzumab), Kadcyla (trastuzumab emtansine), MabThera (rituximab), Phesgo (pertuzumab / trastuzumab) and Tecentriq (atezolizumab)

Key facts

• Medicine name:
  • RoActemra
  • Hemlibra
  • Herceptin
  • Kadcyla
  • MabThera
  • Phesgo
  • Tecentriq
• Active substance:
  • tocilizumab
  • emicizumab
  • trastuzumab
  • trastuzumab emtansine
  • rituximab
  • pertuzumab
  • trastuzumab
  • atezolizumab
• Therapeutic area (MeSH):
  • Arthritis, Rheumatoid
  • Arthritis, Juvenile Rheumatoid
  • Cytokine Release Syndrome
  • Giant Cell Arteritis
  • COVID-19 virus infection
  • Hemophilia A
  • Stomach Neoplasms
  • Breast Neoplasms
  • Lymphoma, Non-Hodgkin
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Carcinoma, Transitional Cell
  • Carcinoma, Non-Small-Cell Lung
  • Urologic Neoplasms
  • Small Cell Lung Carcinoma
• DHPC type:
  Quality defect
• Human ATC codes:
  • L04AC07
  • B02BX06
  • L01XC03
  • L01XC14
  • L01XC02
  • L01XY
• Dissemination date:
  17/08/2023
• Related medicines:
  • Herceptin
  • MabThera
  • Hemlibra
  • Phesgo